$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
028-123456789
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical News
Medical News
Afatinib has significant effect in the treatment of advanced lung squamous cell carcinoma_ Kanghule
2025-10-19 11:44:20
Check Details
The occurrence and treatment options of lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
The therapeutic effect of taking the targeted drug crizotinib in late-stage lung cancer
2025-10-19 11:44:20
Check Details
How effective is afatinib in the treatment of advanced lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
What to do after afatinib is resistant to lung squamous cell carcinoma?
2025-10-19 11:44:20
Check Details
Contraindications and medication precautions for patients taking crizotinib
2025-10-19 11:44:20
Check Details
Crizotinib has significant efficacy in treating ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
The effect of afatinib treatment on patients with lung squamous cell carcinoma
2025-10-19 11:44:20
Check Details
Safety and effectiveness of larotrectinib in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How much will a box of crizotinib cost after it is included in medical insurance in 2021?
2025-10-19 11:44:20
Check Details
Larotinib shows remarkable results in the treatment of NTRK mutation-positive lung cancer patients
2025-10-19 11:44:20
Check Details
Crizotinib has significant anti-cancer effect on ROS1-rearranged advanced non-small cell lung cancer
2025-10-19 11:44:20
Check Details
1
2
...
9906
9907
9908
9909
9910
9911
9912
...
10204
10205
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
What diseases can Upatinib be used for? Which patients are suitable for use?
2
The efficacy of Eltrombopag
3
User Agreement
4
Herceptin Hylecta treats HER2-positive breast cancer and only needs to be injected subcutaneously and only used once every three weeks
5
What is the most important information I should know about WELIREG?
6
How to take and store WELIREG
7
How to take TRUSELTIQ correctly
8
How to deal with LONSURF side effects (1)
9
How to deal with LONSURF side effects (2)
10
Cabozantinib (Cabometyx)-new indication approved
11
What should I pay attention to when using atezolizumab/Tecentriq?
12
Darzalex Faspro, Kyprolis and dexamethasone "three swords combined" to treat multiple myeloma